1 A simulation framework for modeling the within-patient evolutionary dynamics of SARS-CoV-2

- 3 John W Terbot II^{1,2*}, Brandon S. Cooper², Jeffrey M. Good², Jeffrey D. Jensen^{1*}
- ⁴ ¹ Arizona State University, School of Life Sciences, Center for Evolution & Medicine, Tempe,
- 5 Arizona, United States of America
- 6 ² University of Montana, Division of Biological Sciences, Missoula, Montana, United States of
- 7 America
- 8 * jterbot@asu.edu (JWT); jeffrey.d.jensen@asu.edu (JDJ)

9 Abstract

The global impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has led 10 11 to considerable interest in detecting novel beneficial mutations and other genomic changes that may signal the development of variants of concern (VOCs). The ability to accurately detect these 12 changes within individual patient samples is important in enabling early detection of VOCs. 13 14 Such genomic scans for positive selection are best performed via comparison of empirical data to simulated data wherein evolutionary factors, including mutation and recombination rates, 15 16 reproductive and infection dynamics, and purifying and background selection, can be carefully 17 accounted for and parameterized. While there has been work to quantify these factors in SARS-CoV-2, they have yet to be integrated into a baseline model describing intra-host evolutionary 18 dynamics. To construct such a baseline model, we develop a simulation framework that enables 19 one to establish expectations for underlying levels and patterns of patient-level variation. By 20 varying eight key parameters, we evaluated 12,096 different model-parameter combinations and 21 22 compared them to existing empirical data. Of these, 592 models (~5%) were plausible based on the resulting mean expected number of segregating variants. These plausible models shared 23 several commonalities shedding light on intra-host SARS-CoV-2 evolutionary dynamics: severe 24 25 infection bottlenecks, low levels of reproductive skew, and a distribution of fitness effects skewed towards strongly deleterious mutations. We also describe important areas of model 26 27 uncertainty and highlight additional sequence data that may help to further refine a baseline 28 model. This study lays the groundwork for the improved analysis of existing and future SARS-29 CoV-2 within-patient data.

30 Key Words: evolutionary genomics, population genetics, SARS-CoV-2, viral evolution

32 Significance Statement

- 33 Despite its tremendous impact on human health, a comprehensive evolutionary baseline model
- has yet to be developed for studying the within-host population genomics of SARS-CoV-2.
- 35 Importantly, such modeling would enable improved analysis and provide insights into the key
- 36 evolutionary dynamics governing SARS-CoV-2 evolution. Given this need, we have here
- 37 quantified a set of plausible baseline models via large-scale simulation. The commonly shared
- 38 features of these relevant models including severe infection bottlenecks, low levels of progeny
- 39 skew, and a high rate of strongly deleterious mutations lay the foundation for sophisticated
- 40 analyses of SARS-CoV-2 evolution within patients using these baseline models.

41 Introduction

42	The emergence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in late
43	2019 is the most impactful human pathogen to arise thus far in the 21 st century. Since its
44	emergence, SARS-CoV-2 is directly responsible for nearly 8 million deaths as of December
45	2022 (Institute for Health Metrics and Evaluation 2022, Hay et al. 2023). However, the true
46	impact of SARS-CoV-2—considering under-reporting, late reporting, and indirect deaths (e.g.,
47	via strained health care systems)— is likely much greater, with worldwide excess mortality
48	estimated to exceed 14 million as of December 2021 (Wang et al. 2022, Msemburi et al. 2023).
49	Moreover, SARS-CoV-2 continues to persist worldwide and appears likely to become an
50	endemic virus going forward, as observed with other human coronaviruses (HCoV-229E, -NL63,
51	-OC43, and -HKU1; Corman et al. 2018).
52	Understanding the evolutionary dynamics of SARS-CoV-2 and predicting new Variants
53	of Concern (VOCs) that may result in waves of increased infection and mortality remains vital.
54	While the tools for studying these questions as framed via inter-host spread of SARS-CoV-2
55	have been well-developed (Rambaut et al. 2020, O'Toole et al. 2021), the ability to study intra-
56	host evolution of SARS-CoV-2 is considerably less established. Transmission between hosts is
57	an obviously important stage in viral spread; however, inter-host spread is a brief portion of the
58	viral life cycle, with the entirety of viral reproductive activity occurring within a host. Thus,
59	dissecting the intra-host evolutionary dynamics are of key importance in monitoring
60	contemporary and future SARS-CoV-2 spread. In particular, mutations that influence evasion of
61	the host immune system, increase success in cell invasion, and otherwise improve the successful
62	completion of metabolic and reproductive tasks within a host cell could all be of clinical
63	consequence. Given complete information, such mutations would first be detectable within a

single host. While strongly beneficial mutations can eventually become identifiable when
observing inter-host data through their increased prevalence within the meta-population (should
they escape stochastic loss), the evolutionary dynamics that ultimately dictate their spread will be
determined at the intra-host level.

For the viral population within a single patient, these episodic, beneficial mutations may 68 69 be expected to modify patterns of genomic variation in a manner that would deviate from 70 background patterns produced under constantly operating evolutionary processes (e.g., via a 71 selective sweep of the beneficial mutation (Charlesworth and Jensen 2021). As such, as with any 72 natural population, the study of viral intra-host evolution requires the construction of an evolutionary 'null' model to quantify expected baseline levels and patterns of genomic variation 73 (Jensen 2021, Johri et al. 2020, Terbot et al. 2023). At a minimum, a viral baseline model should 74 include mutation, recombination, reproductive dynamics, purifying and background selection, 75 and the history of bottlenecks and growth characterizing patient infection (Irwin et al. 2016). 76 77 Without comparison to such a baseline model, it is not possible to determine if observed withinpatient allele frequencies are attributable to these common evolutionary processes or to the 78 comparatively rare action of positive selection (Barton 1998, Johri et al. 2022b). 79 80 In this study, we present a first attempt to construct such a model and narrow the range of key parameter values governing the intra-host evolutionary dynamics of SARS-CoV-2. Using 81

forward simulations and comparison to existing patient data summarizing intra-host variation, we
identify more and less likely areas of parameter space. We find that transmission and infection
bottlenecks appear to be strongly constrained (*i.e.*, on the order of <5 virions) in plausible
models, consistent with other recent results for SARS-CoV-2 (Lythgoe et al. 2021, Martin and
Koelle 2021, Bendall et al. 2023) and the transmission of other airborne viruses like seasonal

87 influenza (McCrone et al. 2018, Valesano et al. 2019). We also describe important areas of uncertainty and correlations between parameter values. For example, if the distribution of new 88 mutational effects is heavily skewed towards strongly deleterious mutations, the range of 89 uncertainty in other parameter values is inflated. Furthermore, we highlight additional data that 90 may help to further narrow this parameter space. For example, the commonly employed 2% 91 92 minor allele frequency threshold cut-off greatly limits model resolution, and may be improved by higher-coverage sequencing of individual patient samples that increases the confidence in 93 individual single nucleotide polymorphism (SNP) calls. Thus, the presented exploration of the 94 95 SARS-CoV-2 evolutionary parameter space will be valuable in informing future modeling 96 studies, in interpreting newly emerging patient data, and in guiding future data collection.

97 Results

A total of 12096 model-parameter combinations were analyzed (Table 1, Table 2, and Figure 1). 98 The great majority were rejected for generating too few or too many segregating SNPs relative to 99 available empirical data, leaving 592 models remaining (Supplemental Table 1). Due to the 100 nested nature of the models, the feasible model-parameter sets can be readily categorized 101 102 according to the 108 possible combinations of the required parameters. Of these, 18 specific 103 parameter combinations produced viable models, highlighting which parameters are likely to 104 have the strongest influence of intra-host evolution of SARS-CoV-2. We found that all plausible 105 models included a strong infection bottleneck (i.e., a bottleneck under 5 virions appears most consistent with the data, represented here by a bottleneck of 1; Figure 2, Figure 3). Most retained 106 models also had low or moderate mutation rates. Only three models with the highest mutation 107 108 rate were retained. All three of these models were full models using a distribution of fitness 109 effects (DFE) with the largest proportion of strongly deleterious mutations, the highest carrying 110 capacity, and briefest infection duration; the parameter values for recombination and progeny skew varied between these models. In contrast, all 12 required parameter sets using the lowest 111 mutation rate and a severe bottleneck of 1 cleared the SNP threshold, and 5 of the 12 sets with 112 113 the midpoint mutation rate resulted in plausible models. Generally, larger carrying capacities resulted in better fitting models (4/12 parameter sets had plausible models with the lowest value 114 115 of carrying capacity and a bottleneck of 1, 6/12 with the midpoint value for carrying capacity, 116 and 8/12 for the highest carrying capacity).

Within these required parameter sets, there are a total of 112 nested models (1 bottleneck model, 3 with the addition of recombination, 27 with the additions of recombination and progeny skew, and 81 with the additions of recombination, progeny skew, and a DFE); the number of

120 models that cleared the filtering requirement varied considerably between the required parameter

- sets. Briefly, 9 of the 18 required parameter sets had bottleneck models consistent with the
- empirical data (of which 8 had examples of all nested models also clear the threshold), 11 of the
- 123 18 had consistent recombination-only models, 10 out of 18 had consistent recombination +
- 124 progeny skew models, and all 18 had consistent full models. Generally, if a simpler model could
- be accepted, then more complicated models nested within that model also tended to produce
- 126 plausible results. The distribution of these non-rejected models are more fully detailed in Table 3
- and Figure 2. In terms of general patterns, models with strong infection bottlenecks, lower
- 128 progeny skews, and DFEs containing a greater proportion of strongly deleterious mutations were
- 129 more likely to be accepted (Figure 3, and see Discussion).

130 Discussion

131	The evaluation of intra-host population genomic data from SARS-CoV-2 patient samples has the
132	potential to detect signatures of positive selection and allow for the early identification of VOCs.
133	However, it is important to recognize that levels and patterns of genetic variation in a population
134	are the result of a variety of factors including mutation, recombination, reproductive dynamics,
135	purifying and background selection, and the history of bottlenecks and growth characterizing
136	patient infection. One of the key methods of differentiating between these alternative
137	explanations is through comparisons between empirical data and plausible simulated data (Irwin
138	et al. 2016, Johri et al. 2020, Jensen 2021). However, given that the possible model and
139	parameter space is essentially infinite, a key first step in developing an evolutionary baseline
140	model is determining the relevant parameter bounds.
141	Our study supports three main conclusions that help define a feasible parameter space
142	governing intra-host SARS-CoV-2 evolutionary dynamics. First, our results support recent
143	conclusions that SARS-CoV-2 transmission is generally associated with strong infection
144	bottlenecks of one or a few virions (Bendall et al. 2023). Specifically, we found a bottleneck of 1
145	to be the only bottleneck size tested that produced plausible models. However, the unexamined
146	space between 1 and 5 (the midpoint value for bottlenecks) may also produce plausible models
147	as they were not tested in this study. Regardless, a bottleneck of 1 to 4 virions conforms with the
148	recent empirical findings based on patterns of intra-host SARS-CoV-2 variation between likely
149	transmissions pairs (Bendall et al. 2023).
150	Secondly, our results highlight the importance of considering the pervasive effects of

purifying and background selection, via a consideration of the DFE, in constraining levels of
variation segregating above the 2% frequency threshold. The wide-spread production of strongly

deleterious mutations appears necessary to explain the apparent contradiction between the high 153 mutation rates of RNA viruses (Drake and Holland 1999, Elena and Sanjuán 2005, Jensen et al. 154 155 2020) and the generally low number of SNPs identified in patients ((Lythgoe et al. 2021, Valesano et al. 2021, Wang et al. 2021, Bendall et al. 2023, Gu et al. 2023). Given that coding 156 regions comprise most of the SARS-CoV-2 genome, this result is not particularly surprising. 157 158 This importance may be observed in the simulated parameter sets: among the models that 159 accumulated only neutral mutations, 11.8% were plausible; among the models with primarily 160 neutral mutations, 23.9% were plausible; among the models with equivalent rates of neutral and 161 strongly deleterious mutations, 28.4% were plausible; and among the models with primarily strongly deleterious mutations, 42.8% were plausible. Current best estimates of the true DFE 162 underlying SARS-CoV-2 intra-host evolution suggest a bimodal distribution of fitness effects 163 164 (Flynn et al. 2022, Terbot et al. 2023) with peaks centered around strongly deleterious and neutral fitness impacts. At a minimum, between 15-20% of sites in the SARS-CoV-2 genome 165 166 seem to be entirely invariant (Neher 2022), providing a minimum estimate for the proportion of strongly deleterious mutations in the DFE. However, other studies indicate this value is more 167 likely in the range of 40-50% (Flynn et al. 2022, Terbot et al. 2023). Therefore, while the DFE 168 169 most severely skewed towards strongly deleterious mutations produced the most plausible 170 models, it is unlikely to reflect the true proportion of strongly deleterious mutations. However, it 171 is notable that the two other DFE distributions reflecting current best understandings of the true 172 DFE both produced around twice as many viable models as models including only neutral 173 mutations, emphasizing the central importance of purifying selection in the evolution of SARS-174 CoV-2 within patients.

175	Finally, lower progeny skew values produce more plausible models. Specifically, models
176	with progeny skew and containing either lower probabilities of skewed offspring events and/or
177	lower burst sizes were over-represented amongst acceptances (397/555 plausible models or
178	71.5%). Reproduction of SARS-CoV-2 within a host cell is generally non-lytic and instead
179	involves release of new virions through continuous budding (Bar-On et al. 2020; Park et al.
180	2020). The prominence of lower levels of progeny skew in plausible models is consistent with a
181	lack of a single large burst of reproduction (<i>i.e</i> , lower values of burst size). Alternatively, it may
182	be related to the production of sub-genomic RNA which are not packaged directly into offspring
183	virions, but through recombination, mutations present in their sequences can be incorporated into
184	offspring virions (<i>i.e.</i> , lower values of Ξ ; Langsjoen et al. 2020, Gribble et al. 2021).
185	Further model differentiation is limited by current data available for intra-host variation
186	of SARS-CoV-2. The 2% allele frequency cutoff used in this study mirrors the cutoff used in
187	several previous studies (Table 4). While this criterion successfully narrowed the relevant
188	evolutionary parameter space in our simulations, the scarce number of SNPs are insufficient to
189	explore more sophisticated statistics related to the site frequency spectrum or linkage
190	disequilibrium. However, new mutations arising during a typical patient infection will be rare
191	and thus may be missed when applying a frequency-based filter. There is of course an inherent
192	trade-off between including lower frequency SNPs and reducing the confidence in individual
193	SNP calls (Jacot et al. 2021). This trade-off can be partially ameliorated via the generation of
194	high-quality and higher-depth sequencing. A rule of thumb proposed by Lauring (Lauring 2020)
195	suggests that coverage should be ten times the inverse of the variant's frequency. So, a coverage
196	depth of 1000 would be required to confidently detect variants at 1% of the population, a depth
197	of 2000 for a 0.5% variant, and so on.

These general bioinformatic recommendations assume that sequencing data will 198 effectively sample intra-host variation without bias. However, most SARS-CoV-2 sequencing 199 200 protocols rely on targeted PCR or probe-based enrichment of the SARS-CoV-2 genome to reduce background contamination of host nucleotides. Targeted enrichment approaches have 201 been widely used in biology and are usually sensitive to any standing genetic variation that 202 203 impacts the binding efficacy of enrichment probes or primers (Mamanova et al. 2010, Jones and Good 2015). Indeed, assay-dependent effects have been a constant concern during the 204 205 development SARS-CoV-2 sequence protocols as demonstrated by the recurrent need to redesign 206 enrichment primers (e.g., the ARCTIC protocol) to fully sequence the genomes of newly circulating VOCs (Ulhuq et al. 2023). SARS-CoV-2 targeted enrichment is also sensitive to low 207 viral loads (Lam et al. 2021), which could further limit understanding of changes in intra-host 208 209 diversity through the time course of an infection. Given these concerns, technical replication of 210 individual patient samples may be required to reliably detect and quantify the frequency of rare variants. 211

In addition to limitations relating to the detection of rare alleles, our study was also 212 213 unable to consider the impacts of host compartmentalization (*i.e.*, localized subpopulations 214 within different organs and areas of organ systems) on intra-host genetic diversity. Compartmentalization is likely an important factor for SARS-CoV-2 evolution in regard to the 215 216 production of viral reservoirs in prolonged infections or infection of immune-compromised 217 patients (Gonzalez-Reiche et al. 2023, Normandin et al. 2023). However, there is currently 218 insufficient information regarding the number and connectivity of compartments used by SARS-219 CoV-2 to allow for this aspect of model complexity to be reasonably parameterized. As more 220 empirical evidence regarding compartmentalization becomes available, future simulation studies

may be able to incorporate compartmentalization to determine the impacts—specifically the
influence of gene flow and recombination among compartments—on the intra-host population
genetics of SARS-CoV-2.

With that said, based on the currently available data, our study has successfully 224 quantified areas of the SARS-CoV-2 evolutionary parameter space that are most plausible. In 225 226 addition, the simulation framework presented here may be utilized to compare against future 227 sequencing studies, which will likely enable a further narrowing of likely models. However, even 228 the relatively broad parameter space here identified may be utilized to more effectively screen 229 for newly emerging positively selected mutations (e.g., those contributing to the rapid spread of VOCs), and in so doing reduce the traditionally high false-positive rates traditionally associated 230 231 with such selection scans (Johri et al 2020, Johri et al. 2022a). This work will also likely be 232 useful in providing a baseline simulation for studies looking at intra-host population genetics of 233 SARS-CoV-2 over time within a single host. Such studies may also allow for greater 234 discrimination between baseline models while retaining the use of a robust, minimum minor allele frequency by providing information on how genetic variation accumulates (or persists) 235 over the course of an infection within a single patient. 236

237 Materials and Methods

238 Simulations

239 We used the SLiM software package (v4.0.1, Haller and Messer 2023) to conduct forward-intime simulations. We performed all simulations using SLiM's non-Wright-Fisher tick cycle. To 240 represent the single-stranded, haploid genome of one metabolically-active virion, we simulated 241 242 genomes consisting of 30kb. Each tick of the simulation represented approximately one hour, during which all virions in the population produce one 'child virion' excluding cases of progeny 243 244 skew (described further below). We ran four different, nested models to gain insights into the importance of various population genetic factors. The simplest model, hereafter referred to as the 245 bottleneck model, consisted of four parameters: the mutation rate, the initial number of virions 246 drawn from the burn-in period (or bottleneck size), the carrying capacity of the host, and the 247 number of ticks over which the simulation runs *i.e.*, the time between infection and sampling 248 249 (infection duration). The other three models added key factors: recombination, recombination 250 plus progeny skew, and a full model adding recombination, progeny skew, and a DFE. The latter describes the proportion new mutations that are strongly deleterious or neutral. The model and 251 parameter space are summarized in Table 1 and Table 2. We based the tested parameter ranges 252 253 upon the current literature, as recently described in Terbot et al. 2023 unless otherwise stated. Progeny genomes added mutations according to a single, genome-wide mutation rate. 254 255 Contrary to SLiM's default behavior for mutations arising at the same site, the simulation 256 retained only the most recent mutation occurring in a genome. The initial bottleneck was 257 performed by drawing virions from a common burn-in simulation, and the size of this bottleneck 258 reflected the range reported in the literature (Popa et al. 2020, Braun et al. 2021, Lythgoe et al. 259 2021, Martin and Koelle 2021, Bendall et al. 2023). We based the levels used for carrying

260	capacity on the number of virions estimated at peak infection of 10^9 to 10^{11} (Bar-On et al. 2020,
261	Sender et al. 2021). Due to computational constraints, and because this figure represents a census
262	population size as opposed to an effective population size, we scaled the carrying capacity
263	downward. Owing to this scaling of population size, we scaled up the range of mutation and
264	recombination rates to maintain a constant population-scaled product. The duration of infection
265	was chosen to represent a range of potential times to sampling. Given most empirical studies
266	report sampling in terms of days from symptom onset (Table 4), and there is considerable
267	uncertainty regarding the incubation time of SARS-CoV-2 from initial infection to symptom
268	presentation (Bar-On et al. 2020, Lauer et al. 2020, Li et al. 2020, Du et al. 2022, Wu et al.
269	2022), this range extends from brief (7 days) to extended (42 days).
270	To model recombination, we used a single parameter for the genome-wide recombination
271	rate. For each virion, the simulation chose another random virion to serve as the recombination
272	partner; and the simulation used this recombination partner for all progeny produced by the focal
273	virion in that tick cycle, including those experiencing progeny skew. We used a multiple-merger
274	coalescent model of progeny skew (Irwin et al. 2016) which required two parameters: Ξ

corresponding to the probability of a virion having multiple reproduction events in a single tick,

and the size of this reproductive burst. Values of Ξ represent the eclipse time of a virion (10

hours, *i.e.*, a value of $\Xi = 0.1$) as the max rate (Bar-On et al. 2020) or the product of this eclipse

time and the number of virions present in a cell that is actively budding virions (*i.e.*, 100000

virions multiplied by 10 hours, or a value of $\Xi = 0.000001$) as the minimum rate (Sender et al.

280 2021). The geometric mean of the minimum and maximum value (0.001) was used as the

midpoint value. We selected the highest level of burst size by determining the largest possible

burst that could still be completed with the maximum levels of Ξ and carrying capacity and the

requested computing resources; we selected lower levels as proportions of that maximum value.
Finally, we parameterized the DFE as the ratio of strongly deleterious relative to neutral
mutations.

Simulations used a common, burn-in source population which was created using a full-286 model simulation run for 25,000 ticks at the highest value of carrying capacity and the mid-level 287 288 value for all other parameters. We replicated each parameter combination 5 times. Therefore, we 289 ran a total of 12,096 model-parameter combinations (represented visually in Figure 1), resulting 290 in 60,480 replicates. To simulate variation in sequencing depth of empirical studies, we 291 independently sampled 100 and 1000 genomes and stored them as .ms files. A total of 26 replicates failed to complete due to requiring more than the allotted computational resources and 292 were excluded from further analysis (Supplemental Table 2). 293

294

295 Simulation Assessment

296 Using the scikit-allel package (Miles et al. 2021) and custom python script (Rossum and Drake 2009), we calculated a set of summary statistics for each .ms file. The primary statistic we used 297 to identify models resulting in levels of variation similar to that observed in empirical patient 298 299 samples was the total number of SNPs (often referred to as intra-host single nucleotide variations 300 or iSNVs in the SARS-CoV-2 literature). We compared the simulated data to multiple recent 301 studies that have sought to quantify the amount of intra-host variation in SARS-CoV-2 (Lythgoe 302 et al. 2021, Valesano et al. 2021, Wang et al. 2021, Bendall et al. 2023, Gu et al. 2023). To make this comparison, we applied filtering criteria to the simulated data reflecting that implemented in 303 304 the empirical data (*i.e.*, removing variants segregating below 2% frequency). From this existing 305 literature, the number of SNPs found within an intra-host population of SARS-CoV-2 clearing

- this frequency threshold tends to be 5 or fewer (Table 4). Additionally, we required each
- 307 parameter combination to clear this threshold for both the 100 and 1000 genome sampling
- 308 schemes. We performed model filtering, and figure creation was performed using a custom R
- script (R Core Team 2022) and the packages ggplot2 (Wickham 2016) and gridExtra (Auguie
- 2017). All eidos, bash, python, and R scripts have been deposited on github
- 311 (https://github.com/jwterbot2/SARS-CoV-2_InitialBaselineModel)

312 Supplementary Material

313 Supplementary tables and figures are available in a linked file for the purposes of review.

314 Acknowledgements

- Research reported in this manuscript was supported by the National Institute of General Medical
- Sciences of the National Institutes of Health (NIH) under Award Number P30GM140963 (to
- JMG and BSC). NIH awards R35GM124701 (BSC) and R35GM139383 (JDJ) also supported
- this work. The funders had no role in study design, data collection and analysis, decision to
- publish, or preparation of the manuscript. We are grateful to Parul Johri and Vivak Soni for their
- advice regarding simulation design. We would also like to thank the computing resources used
- during this study: the common burn-in was run on the Agave computing cluster at ASU and
- simulation replicates were run using the Open Science Pool resources (OSG 2006, Pordes et al.
- 323 2007, Sfiligoi et al. 2009).

- 324 Data Availability
- 325 Scripts and code used in this study along with a copy of data used to generate figures are
- 326 available online via github (<u>https://github.com/jwterbot2/SARS-CoV-2_InitialBaselineModel</u>).

- 327 Literature Cited
- 328 Auguie B. 2017. gridExtra: Miscellaneous Functions for 'Grid' Graphics. https://cran.r-
- 329 <u>project.org/package=gridExtra</u>.
- Bar-On YM, Flamholz A, Phillips R, Milo R. 2020. SARS-CoV-2 (COVID-19) by the numbers.
- eLife. 9. doi: 10.7554/eLife.57309.
- Barton NH. 1998. The effect of hitch-hiking on neutral genealogies. Genetical Research. 72:123–
- 333 133. doi: 10.1017/S0016672398003462.
- Bendall EE et al. 2023. Rapid transmission and tight bottlenecks constrain the evolution of
- highly transmissible SARS-CoV-2 variants. Nat Commun. 14:272. doi: 10.1038/s41467-
- **336** 023-36001-5.
- Braun KM et al. 2021. Acute SARS-CoV-2 infections harbor limited within-host diversity and
 transmit via tight transmission bottlenecks. PLoS Pathogens. 17:e1009849. doi:
- 339 10.1371/journal.ppat.1009849.
- 340 Charlesworth B, Jensen JD. 2021. Effects of selection at linked sites on patterns of genetic
- variability. Annu Rev of Ecol Evol and Systematics. 52:177–197. doi: 10.1146/annurevecolsys-010621-044528.
- Corman VM, Muth D, Niemeyer D, Drosten C. 2018. Hosts and sources of endemic human
- 344 coronaviruses. In: *Advances in Viral Research*. Academic Press: Cambridge, MA pp.
- 345 163–188. doi: 10.1016/bs.aivir.2018.01.001.
- 346 Drake JW, Holland JJ. 1999. Mutation rates among RNA viruses. Proc Natl Acad Sci U S A.
- 347 96:13910–13913. doi: 10.1073/pnas.96.24.13910.
- 348 Du Z et al. 2022. Shorter serial intervals and incubation periods in SARS-CoV-2 variants than
- the SARS-CoV-2 ancestral strain. J Travel Medicine. 29:1–3. doi: 10.1093/jtm/taac052.

350	Elena SF, Sanjuán R. 2005. Adaptive value of high mutation rates of RNA viruses: separating
351	causes from consequences. J Virology. 79:11555–11558. doi: 10.1128/JVI.79.18.11555-
352	11558.2005.
353	Flynn JM et al. 2022. Comprehensive fitness landscape of SARS-CoV-2 M ^{pro} reveals insights
354	into viral resistance mechanisms. eLife. 11:1-27. doi: 10.7554/eLife.77433.
355	Gonzalez-Reiche AS et al. 2023. Sequential intrahost evolution and onward transmission of
356	SARS-CoV-2 variants. Nat Commun. 14:3235. doi: 10.1038/s41467-023-38867-x
357	Gribble J et al. 2021. The coronavirus proofreading exoribonuclease mediates extensive viral
358	recombination. PLoS Pathogens. 17:e1009226. doi: 10.1371/journal.ppat.1009226.
359	Gu H et al. 2023. Within-host genetic diversity of SARS-CoV-2 lineages in unvaccinated and
360	vaccinated individuals. Nat Commun. 14:1793. doi: 10.1038/s41467-023-37468-y.
361	Haller BC, Messer PW. 2023. SLiM 4: Multispecies eco-evolutionary modeling. The American
362	Naturalist. 201:E000-E000. doi: 10.1086/723601.
363	Hay SI, Murray CJL. 2023. Conflicting COVID-19 excess mortality estimates – Authors' reply.
364	The Lancet. 401:433-434. doi: 10.1016/S0140-6736(23)00227-1.
365	Institute for Health Metrics and Evaluation. 2022. Covid-19 Projections.
366	https://covid19.healthdata.org/global?view=cumulative-deaths&tab=trend. (July 13,
367	2023)
368	Irwin KK et al. 2016. On the importance of skewed offspring distributions and background
369	selection in virus population genetics. Heredity. 117:393–399. doi: 10.1038/hdy.2016.58.
370	Jacot D, Pillonel T, Greub G, Bertelli C. 2021. Assessment of SARS-CoV-2 genome sequencing:
371	quality criteria and low-frequency variants. J Clinical Microbiology. 59:1-10. doi:
372	10.1128/JCM.00944-21.

- Jensen JD. 2021. Studying population genetic processes in viruses: From drug-resistance
- evolution to patient infection dynamics. In: *Encyclopedia of Virology*. Elsevier pp. 227–
- 375 232. doi: 10.1016/B978-0-12-814515-9.00113-2.
- Jensen JD, Stikeleather RA, Kowalik TF, Lynch M. 2020. Imposed mutational meltdown as an
- antiviral strategy. Evolution. 74:2549–2559. doi: 10.1111/evo.14107.
- Johri P et al. 2022a. Recommendations for improving statistical inference in population
- genomics. PLoS Biology. 20:e3001669. doi: 10.1371/journal.pbio.3001669.
- Johri P, Charlesworth B, Jensen JD. 2020. Toward an evolutionarily appropriate null model:
- jointly inferring demography and purifying selection. Genetics. 215:173–192. doi:
- 382 10.1534/genetics.119.303002.
- Johri P, Stephan W, Jensen JD. 2022b. Soft selective sweeps: Addressing new definitions,
- evaluating competing models, and interpreting empirical outliers. PLoS Genetics.
- 385 18:e1010022. doi: 10.1371/journal.pgen.1010022.
- Jones MR, Good JM. 2016. Targeted capture in evolutionary and ecological genomics. Mol Ecol.
- 387 25:185–202. doi: 10.1111/mec.13304.
- Lam C et al. 2021. SARS-CoV-2 Genome sequencing methods differ in their abilities to detect

389 variants from low-viral-load samples. J Clinical Microbiology. 59. doi:

- **390** 10.1128/JCM.01046-21.
- Langsjoen RM, Muruato AE, Kunkel SR, Jaworski E, Routh A. 2020. Differential Alphavirus
- 392 defective RNA diversity between intracellular and extracellular compartments is driven
- by subgenomic recombination events. mBio. 11:1–20. doi: 10.1128/mBio.00731-20.

- Lauer SA et al. 2020. The incubation period of coronavirus disease 2019 (CoVID-19) from
- 395 publicly reported confirmed cases: Estimation and application. Annals of Internal
- 396 Medicine. 172:577–582. doi: 10.7326/M20-0504.
- 397 Lauring AS. 2020. Within-host viral diversity: A window into viral evolution. Annu Rev

398 Virology. 7:63–81. doi: 10.1146/annurev-virology-010320-061642.

- Li Q et al. 2020. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected
- 400 pneumonia. New England Journal of Medicine. 382:1199–1207. doi:
- 401 10.1056/nejmoa2001316.
- 402 Lythgoe KA et al. 2021. SARS-CoV-2 within-host diversity and transmission. Science. 372. doi:

403 10.1126/science.abg0821.

404 Mamanova L et al. 2010. Target-enrichment strategies for next-generation sequencing. Nat

405 Meth. 7:111–118. doi: 10.1038/nmeth.1419.

- 406 Martin MA, Koelle K. 2021. Comment on "Genomic epidemiology of superspreading events in
- 407 Austria reveals mutational dynamics and transmission properties of SARS-CoV-2". Sci

408 Transl Med. 13:eabh1803. doi: 10.1126/scitranslmed.abh1803.

- 409 McCrone JT et al. 2018. Stochastic processes constrain the within and between host evolution of
- 410 influenza virus. eLife. 7. doi: 10.7554/eLife.35962.
- 411 Miles A et al. 2021. cggh/scikit-allel: v1.3.3. doi: 10.5281/zenodo.4759368.
- 412 Msemburi W et al. 2023. The WHO estimates of excess mortality associated with the COVID-19
- 413 pandemic. Nature. 613:130–137. doi: 10.1038/s41586-022-05522-2.
- 414 Neher RA. 2022. Contributions of adaptation and purifying selection to SARS-CoV-2 evolution.
- 415 Virus Evol. 8:2022.08.22.504731. doi: 10.1093/ve/veac113.

- 416 Normandin E et al. 2023. High-depth sequencing characterization of viral dynamics across
- 417 tissues in fatal COVID-19 reveals compartmentalized infection. Nat Commun. 14:574.
- 418 doi: 10.1038/s41467-022-34256-y.
- 419 O'Toole Á et al. 2021. Assignment of epidemiological lineages in an emerging pandemic using
- 420 the pangolin tool. Virus Evol. 7:1–9. doi: 10.1093/ve/veab064.
- 421 OSG. 2006. OSPool. doi: 10.21231/906P-4D78.
- Park WB et al. 2020. Virus isolation from the first patient with sars-cov-2 in Korea. J Korean
 Medical Science. 35:10–14. doi: 10.3346/jkms.2020.35.e84.
- 424 Popa A et al. 2020. Genomic epidemiology of superspreading events in Austria reveals
- 425 mutational dynamics and transmission properties of SARS-CoV-2. Science Translational
- 426 Medicine. 12:2555. doi: 10.1126/scitranslmed.abe2555.
- 427 Pordes R et al. 2007. The open science grid. J Physics: Conference Series. 78:012057. doi:
- 428 10.1088/1742-6596/78/1/012057.
- 429 R Core Team. 2018. R: A Language and Environment for Statistical Computing. R Foundation
- 430 for Statistical Computing: Vienna, Austria <u>https://www.R-project.org/</u>.
- 431 Rambaut A et al. 2020. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist
- 432 genomic epidemiology. Nat Microbiol. 5:1403–1407. doi: 10.1038/s41564-020-0770-5.
- 433 Sender R et al. 2021. The total number and mass of SARS-CoV-2 virions. Proc Natl Acad Sci U
- 434 S A. 118:1–9. doi: 10.1073/pnas.2024815118.
- 435 Sfiligoi I et al. 2009. The pilot way to grid resources using glideinWMS. In: 2009 WRI World
- 436 *Congress on Computer Science and Information Engineering*. IEEE pp. 428–432. doi:
- 437 10.1109/CSIE.2009.950.

- 438 Terbot JW et al. 2023. Developing an appropriate evolutionary baseline model for the study of
- 439 SARS-CoV-2 patient samples. PLoS Pathogens. 19:e1011265. doi:
- 440 10.1371/journal.ppat.1011265.
- 441 Ulhuq FR et al. 2023. Analysis of the ARTIC V4 and V4.1 SARS-CoV-2 primers and their
- 442 impact on the detection of Omicron BA.1 and BA.2 lineage-defining mutations.
- 443 Microbial Genomics. 9:2022.12.01.22282842. doi: 10.1099/mgen.0.000991.
- Valesano AL et al. 2020. Influenza B viruses exhibit lower within-host diversity than influenza
 A viruses in human hosts. J Virology. 94. doi: 10.1128/JVI.01710-19.
- 446 Valesano AL et al. 2021. Temporal dynamics of SARS-CoV-2 mutation accumulation within
- and across infected hosts. PLoS Pathogens. 17:e1009499. doi:
- 448 10.1371/journal.ppat.1009499.Van
- 449 Rossum G, Drake FL. 2009. Python 3 Reference Manual. doi: 10.5555/1593511.
- 450 Wang H et al. 2022. Estimating excess mortality due to the COVID-19 pandemic: a systematic
- 451 analysis of COVID-19-related mortality, 2020–21. The Lancet. 399:1513–1536. doi:
- 452 10.1016/S0140-6736(21)02796-3.
- 453 Wang Y et al. 2021. Intra-host variation and evolutionary dynamics of SARS-CoV-2 populations
- 454 in COVID-19 patients. Genome Medicine. 13:30. doi: 10.1186/s13073-021-00847-5.
- 455 Wickham H. 2016. ggplot2: Elegant Graphics for Data Analysis. doi: 10.1007/978-3-319-24277-
- 456 4.
- 457 Wu Y et al. 2022. Incubation Period of COVID-19 Caused by Unique SARS-CoV-2 Strains.
- 458 JAMA Network Open. 5:e2228008. doi: 10.1001/jamanetworkopen.2022.28008.

- 459 Tables and Figures
- 460 Table 1. Outline of Model Complexity
- 461 Each row represents a nested model which includes all parameters in that row and from rows above it.
- 462 Number of parameters added by each stage is detailed in column "+k" and the specific parameters added
- are described in the rightmost column.

Model	+ <i>k</i>	Parameters
Bottleneck	4	Bottleneck, Mutation Rate (μ), Infection Duration, Carrying Capacity (K)
+ Recombination	1	Recombination Rate (R)
+ Progeny Skew	2	Probability of Multiple Coalescent Event (<i>Ξ</i>), Burst Size
+ DFE	1	Ratio of neutral to strongly deleterious mutations

464 Table 2. Parameter Values Used in Models

Each parameter, other than infection duration, had three possible levels: a low point estimate, a high point estimate, and a value representing a midpoint value. The column labeled "Burn-In" details the parameter levels used during the common burn-in; note that aside from infection duration and carrying capacity, all parameter levels used were the midpoint level. The highest carrying capacity and an extended infection duration were used to allow mutations to accumulate and begin to reach equilibrium as may be expected across the entire metapopulation of a pathogen during a prolonged pandemic.

	Burn-In	Lowest	Low	Midpoint	High
Initial Bottleneck	N/A	N/A	1	5	100
Infection Duration	25e3	168 (7 days)	336 (14 days)	672 (28 Days)	1008 (42 Days)
Mutation Rate	2.135e-6	N/A	2.135e-7	2.135e-6	2.135e-5
Carrying Capacity	1e5	N/A	5e3	5e4	1e5
Recombination Rate	5.5e-5	N/A	1e-5	5.5e-5	1e-4
Progeny Skew Probability	0.003	N/A	0.0001	0.003	0.1
Progeny Skew Amount	100	N/A	20	100	200
DFE (Neutral:Deleterious)	1:1	N/A	4:1	1:1	1:4

471 Table 3: Number of Plausible Models Given Required Parameters and Model Complexity

472 Counts and percentage of nested models within a given set of values for the required parameters carrying capacity, mutation rate, and infection

473 duration detailed in the first three columns (the initial bottleneck for all accepted models was the low value or a single virion). Each set of required

- 474 parameters had a single bottleneck model (columns 4 and 5), 3 recombination models (columns 6 and 7), 27 progeny skew models (columns 8 and
- 475 9), and 81 full models (columns 10 and 11). The final two columns represent the count and percentage of accepted models (out of a possible 112)
- 476 given a set of required parameters.

Infection Duration	Mutation Rate (μ)	Carrying Capacity (<i>K</i>)	Bottleneck Count	Bottleneck Percent	Recomb. Count	Recomb. Percent	Prog. Skew Count	Prog. Skew Percent	Full Count	Full Percent	All Count	All Percent
Lowest	Low	Low	1	100.00%	2	66.70%	6	22.20%	55	67.90%	64	57.10%
Lowest	Low	Midpoint	1	100.00%	3	100.00%	14	51.90%	56	69.10%	74	66.10%
Lowest	Low	High	1	100.00%	2	66.70%	19	70.40%	39	48.10%	61	54.50%
Lowest	Midpoint	Midpoint	1	100.00%	3	100.00%	8	29.60%	37	45.70%	49	43.80%
Lowest	Midpoint	High	1	100.00%	3	100.00%	11	40.70%	43	53.10%	58	51.80%
Lowest	High	High	0	0.00%	0	0.00%	0	0.00%	3	3.70%	3	2.70%
Low	Low	Low	0	0.00%	0	0.00%	0	0.00%	28	34.60%	28	25.00%
Low	Low	Midpoint	1	100.00%	3	100.00%	10	37.00%	33	40.70%	47	42.00%
Low	Low	High	0	0.00%	3	100.00%	12	44.40%	40	49.40%	52	46.40%
Low	Midpoint	Midpoint	0	0.00%	0	0.00%	0	0.00%	9	11.10%	9	8.00%
Low	Midpoint	High	0	0.00%	3	100.00%	3	11.10%	21	25.90%	27	24.10%
Midpoint	Low	Low	0	0.00%	0	0.00%	0	0.00%	9	11.10%	9	8.00%
Midpoint	Low	Midpoint	1	100.00%	2	66.70%	1	3.70%	23	28.40%	27	24.10%
Midpoint	Low	High	1	100.00%	3	100.00%	9	33.30%	25	30.90%	38	33.90%
Midpoint	Midpoint	High	0	0.00%	0	0.00%	0	0.00%	3	3.70%	3	2.70%
High	Low	Low	0	0.00%	0	0.00%	0	0.00%	5	6.20%	5	4.50%
High	Low	Midpoint	0	0.00%	0	0.00%	0	0.00%	10	12.30%	10	8.90%
High	Low	High	1	100.00%	1	33.30%	0	0.00%	23	28.40%	25	22.30%

478 Table 4. Summary of Empirical Studies Referenced

479 Sampling schema and results from empirical studies that reported the number of intra-host SNPs identified in patient samples. Note that all studies

480 apart from Lythgoe et al. 2021 utilized serial sampling within at least one patient during their data collection; this did not impact their reported

481 number of intra-host SNPs, but did allow for confirmation of SNPs as true positives.

Paper	Time to Sample	MAF Filter	Intra-host SNPs 482
Lythgoe et al. 2021	"symptomatic individuals on admission to the hospital"	3%	1.4 (mean) 483
Valesano et al. 2021	-7 to 20 days post symptom onset	2%	1 (median); 0-2 (IQR)
Wang et al. 2021	10 to 37 days post-symptom onset (18.09 days (mean))	5%	7.33 (mean); 1-23 (Rang 19)4
Bendall et al. 2023	Symptoms and positive test within 7 days	2%*	~0.82 (mean); 0-5 (Range)_
Gu et al. 2023	With 5 days of symptom onset (2.3 days (mean))	2.50%	485 10.05 (mean); 5 (median)

486 * Intra-host SNP had to clear MAF filter in two technical replicates



Figure 1. Representations of the total parameter space for models' required parameters. Each required parameter [*i.e.*, bottleneck size, infection duration, mutation rate (μ), and carrying capacity (K)] is represented by a node. Line color and shape correspond to parameter value: dotted, red is lowest; solid, orange is low (the lowest value for bottleneck size, μ , and K); dashed, green is the mid-point value; and dotted-dashed, blue is the high value. The asterisk (*) denotes the only area of parameter space that had plausible models: those with bottlenecks of 1 (see Figure 2).



Figure 2. Parameter space for all plausible models. Line color and shape correspond to the parameter
values as in Figure 1. For each set of required parameters, a box is included that contains the fraction of
plausible models out of the total number of models using that set. Further information on the specific
models which were plausible is detailed in Table 3.



Figure 3. Each line represents the range of filtered SNPs for a particular model using a sampling of 1000 501 502 genomes, and each point is the mean of that model's replicates. All models in this figure used the lowest 503 bottleneck size (*i.e.*, 1); the carrying capacity used increases in panels from left to right, and the value of the mutation rate used increases in panels from top to bottom. Within each panel, dashed lines separate 504 505 models into subpanels with different infection durations, increasing from left to right. Within each 506 subpanel the order of the models is the same and is detailed in Supplemental Table 3. The blue, horizontal 507 line represents the threshold of 5 SNPs used in this study to accept or reject a potential model (note that 508 Y-axes differ by row). Models with a mean value lower than this line (but not zero) were accepted as 509 plausible. Similar figures for models using larger bottlenecks are available as Supplemental Figures 1 and 510 2.

512

Supplemental Table 1. List of parameter levels for all plausible models.

μ	Bottleneck Size	К	Infection Duration	Recombination	Ξ	Burst Size	DFE
Low	Low	Low	Lowest	n/a	n/a	n/a	n/a
Low	Low	Low	Lowest	Low	n/a	n/a	n/a
Low	Low	Low	Lowest	Low	Low	Low	n/a
Low	Low	Low	Lowest	Low	Low	Mid	n/a
Low	Low	Low	Lowest	Low	Mid	Low	n/a
Low	Low	Low	Lowest	Low	Low	Low	4:1
Low	Low	Low	Lowest	Low	Low	Mid	4:1
Low	Low	Low	Lowest	Low	Low	High	4:1
Low	Low	Low	Lowest	Low	Mid	Low	4:1
Low	Low	Low	Lowest	Low	Mid	High	4:1
Low	Low	Low	Lowest	Low	Low	Low	1:1
Low	Low	Low	Lowest	Low	Low	Mid	1:1
Low	Low	Low	Lowest	Low	Low	High	1:1
Low	Low	Low	Lowest	Low	Mid	Low	1:1
Low	Low	Low	Lowest	Low	Mid	Mid	1:1
Low	Low	Low	Lowest	Low	Mid	High	1:1
Low	Low	Low	Lowest	Low	Low	Low	1:4
Low	Low	Low	Lowest	Low	Low	Mid	1:4
Low	Low	Low	Lowest	Low	Low	High	1:4
Low	Low	Low	Lowest	Low	Mid	Mid	1:4
Low	Low	Low	Lowest	Low	Mid	High	1:4
Low	Low	Low	Lowest	Low	High	Mid	1:4
Low	Low	Low	Lowest	Low	High	High	1:4
Low	Low	Low	Lowest	Mid	n/a	n/a	n/a
Low	Low	Low	Lowest	Mid	Low	Low	n/a
Low	Low	Low	Lowest	Mid	Mid	Low	n/a
Low	Low	Low	Lowest	Mid	Low	Low	4:1
Low	Low	Low	Lowest	Mid	Mid	Low	4:1
Low	Low	Low	Lowest	Mid	Mid	High	4:1
Low	Low	Low	Lowest	Mid	Low	Low	1:1
Low	Low	Low	Lowest	Mid	Low	Mid	1:1
Low	Low	Low	Lowest	Mid	Low	High	1:1
Low	Low	Low	Lowest	Mid	Mid	Low	1:1
Low	Low	Low	Lowest	Mid	Mid	High	1:1
Low	Low	Low	Lowest	Mid	Low	Low	1:4
Low	Low	Low	Lowest	Mid	Low	Mid	1:4
Low	Low	Low	Lowest	Mid	Low	High	1:4
Low	Low	Low	Lowest	Mid	Mid	Low	1:4
Low	Low	Low	Lowest	Mid	Mid	Mid	1:4

μ	Bottleneck Size	К	Infection Duration	Recombination	Ξ	Burst Size	DFE
Low	Low	Low	Lowest	Mid	Mid	High	1:4
Low	Low	Low	Lowest	Mid	High	Low	1:4
Low	Low	Low	Lowest	Mid	High	Mid	1:4
Low	Low	Low	Lowest	Mid	High	High	1:4
Low	Low	Low	Lowest	High	Low	Low	n/a
Low	Low	Low	Lowest	High	Low	Low	4:1
Low	Low	Low	Lowest	High	Low	High	4:1
Low	Low	Low	Lowest	High	Mid	Low	4:1
Low	Low	Low	Lowest	High	Mid	High	4:1
Low	Low	Low	Lowest	High	Low	Low	1:1
Low	Low	Low	Lowest	High	Low	Mid	1:1
Low	Low	Low	Lowest	High	Low	High	1:1
Low	Low	Low	Lowest	High	Mid	Low	1:1
Low	Low	Low	Lowest	High	Mid	Mid	1:1
Low	Low	Low	Lowest	High	Mid	High	1:1
Low	Low	Low	Lowest	High	High	Low	1:1
Low	Low	Low	Lowest	High	Low	Low	1:4
Low	Low	Low	Lowest	High	Low	Mid	1:4
Low	Low	Low	Lowest	High	Low	High	1:4
Low	Low	Low	Lowest	High	Mid	Low	1:4
Low	Low	Low	Lowest	High	Mid	Mid	1:4
Low	Low	Low	Lowest	High	Mid	High	1:4
Low	Low	Low	Lowest	High	High	Low	1:4
Low	Low	Low	Lowest	High	High	Mid	1:4
Low	Low	Low	Lowest	High	High	High	1:4
Low	Low	Mid	Lowest	n/a	n/a	n/a	n/a
Low	Low	Mid	Lowest	Low	n/a	n/a	n/a
Low	Low	Mid	Lowest	Low	Low	Mid	n/a
Low	Low	Mid	Lowest	Low	Mid	Mid	n/a
Low	Low	Mid	Lowest	Low	High	Low	n/a
Low	Low	Mid	Lowest	Low	Low	Mid	4:1
Low	Low	Mid	Lowest	Low	Low	High	4:1
Low	Low	Mid	Lowest	Low	Mid	Low	4:1
Low	Low	Mid	Lowest	Low	Mid	Mid	4:1
Low	Low	Mid	Lowest	Low	High	Low	4:1
Low	Low	Mid	Lowest	Low	High	Mid	4:1
Low	Low	Mid	Lowest	Low	High	High	4:1
Low	Low	Mid	Lowest	Low	Low	Low	1:1
Low	Low	Mid	Lowest	Low	Low	Mid	1:1
Low	Low	Mid	Lowest	Low	Mid	Low	1:1
Low	Low	Mid	Lowest	Low	Mid	Mid	1:1

μ	Bottleneck Size	К	Infection Duration	Recombination	Ξ	Burst Size	DFE
Low	Low	Mid	Lowest	Low	Mid	High	1:1
Low	Low	Mid	Lowest	Low	High	Low	1:1
Low	Low	Mid	Lowest	Low	High	Mid	1:1
Low	Low	Mid	Lowest	Low	High	High	1:1
Low	Low	Mid	Lowest	Low	Mid	Low	1:4
Low	Low	Mid	Lowest	Low	Mid	Mid	1:4
Low	Low	Mid	Lowest	Low	Mid	High	1:4
Low	Low	Mid	Lowest	Low	High	Mid	1:4
Low	Low	Mid	Lowest	Low	High	High	1:4
Low	Low	Mid	Lowest	Mid	n/a	n/a	n/a
Low	Low	Mid	Lowest	Mid	Low	Low	n/a
Low	Low	Mid	Lowest	Mid	Low	Mid	n/a
Low	Low	Mid	Lowest	Mid	Mid	Mid	n/a
Low	Low	Mid	Lowest	Mid	High	Low	n/a
Low	Low	Mid	Lowest	Mid	High	Mid	n/a
Low	Low	Mid	Lowest	Mid	Low	Low	4:1
Low	Low	Mid	Lowest	Mid	Low	Mid	4:1
Low	Low	Mid	Lowest	Mid	Low	High	4:1
Low	Low	Mid	Lowest	Mid	Mid	Mid	4:1
Low	Low	Mid	Lowest	Mid	Mid	High	4:1
Low	Low	Mid	Lowest	Mid	High	Low	4:1
Low	Low	Mid	Lowest	Mid	High	Mid	4:1
Low	Low	Mid	Lowest	Mid	High	High	4:1
Low	Low	Mid	Lowest	Mid	Low	Low	1:1
Low	Low	Mid	Lowest	Mid	Low	High	1:1
Low	Low	Mid	Lowest	Mid	Mid	Mid	1:1
Low	Low	Mid	Lowest	Mid	Mid	High	1:1
Low	Low	Mid	Lowest	Mid	High	Mid	1:1
Low	Low	Mid	Lowest	Mid	High	High	1:1
Low	Low	Mid	Lowest	Mid	Low	Low	1:4
Low	Low	Mid	Lowest	Mid	Mid	Mid	1:4
Low	Low	Mid	Lowest	Mid	Mid	High	1:4
Low	Low	Mid	Lowest	Mid	High	Mid	1:4
Low	Low	Mid	Lowest	Mid	High	High	1:4
Low	Low	Mid	Lowest	High	n/a	n/a	n/a
Low	Low	Mid	Lowest	High	Low	Low	n/a
Low	Low	Mid	Lowest	High	Low	Mid	n/a
Low	Low	Mid	Lowest	High	Mid	Low	n/a
Low	Low	Mid	Lowest	High	Mid	Mid	n/a
Low	Low	Mid	Lowest	High	High	Low	n/a
Low	Low	Mid	Lowest	High	High	High	n/a

μ	Bottleneck Size	К	Infection Duration	Recombination	Ξ	Burst Size	DFE
Low	Low	Mid	Lowest	High	Low	Low	4:1
Low	Low	Mid	Lowest	High	Low	Mid	4:1
Low	Low	Mid	Lowest	High	Low	High	4:1
Low	Low	Mid	Lowest	High	Mid	Mid	4:1
Low	Low	Mid	Lowest	High	High	Mid	4:1
Low	Low	Mid	Lowest	High	High	High	4:1
Low	Low	Mid	Lowest	High	Low	Mid	1:1
Low	Low	Mid	Lowest	High	Low	High	1:1
Low	Low	Mid	Lowest	High	Mid	High	1:1
Low	Low	Mid	Lowest	High	High	Low	1:1
Low	Low	Mid	Lowest	High	High	Mid	1:1
Low	Low	Mid	Lowest	High	High	High	1:1
Low	Low	Mid	Lowest	High	Low	Mid	1:4
Low	Low	Mid	Lowest	High	Mid	Mid	1:4
Low	Low	Mid	Lowest	High	Mid	High	1:4
Low	Low	Mid	Lowest	High	High	Mid	1:4
Low	Low	Mid	Lowest	High	High	High	1:4
Low	Low	High	Lowest	n/a	n/a	n/a	n/a
Low	Low	High	Lowest	Low	Low	Mid	n/a
Low	Low	High	Lowest	Low	Low	High	n/a
Low	Low	High	Lowest	Low	Mid	Low	n/a
Low	Low	High	Lowest	Low	Mid	Mid	n/a
Low	Low	High	Lowest	Low	High	Low	n/a
Low	Low	High	Lowest	Low	High	High	n/a
Low	Low	High	Lowest	Low	Low	Low	4:1
Low	Low	High	Lowest	Low	Mid	Low	4:1
Low	Low	High	Lowest	Low	Mid	High	4:1
Low	Low	High	Lowest	Low	High	Mid	4:1
Low	Low	High	Lowest	Low	High	High	4:1
Low	Low	High	Lowest	Low	Mid	Low	1:1
Low	Low	High	Lowest	Low	Mid	Mid	1:1
Low	Low	High	Lowest	Low	Mid	High	1:1
Low	Low	High	Lowest	Low	High	Mid	1:1
Low	Low	High	Lowest	Low	High	High	1:1
Low	Low	High	Lowest	Low	Mid	High	1:4
Low	Low	High	Lowest	Low	High	High	1:4
Low	Low	High	Lowest	Mid	n/a	n/a	n/a
Low	Low	High	Lowest	Mid	Low	Low	n/a
Low	Low	High	Lowest	Mid	Low	Mid	n/a
Low	Low	High	Lowest	Mid	Low	High	n/a
Low	Low	High	Lowest	Mid	Mid	Low	n/a

μ	Bottleneck Size	К	Infection Duration	Recombination	Ξ	Burst Size	DFE
Low	Low	High	Lowest	Mid	Mid	Mid	n/a
Low	Low	High	Lowest	Mid	Mid	High	n/a
Low	Low	High	Lowest	Mid	High	Mid	n/a
Low	Low	High	Lowest	Mid	High	High	n/a
Low	Low	High	Lowest	Mid	Low	Low	4:1
Low	Low	High	Lowest	Mid	Low	High	4:1
Low	Low	High	Lowest	Mid	Mid	Mid	4:1
Low	Low	High	Lowest	Mid	Mid	High	4:1
Low	Low	High	Lowest	Mid	High	Low	4:1
Low	Low	High	Lowest	Mid	High	Mid	4:1
Low	Low	High	Lowest	Mid	High	High	4:1
Low	Low	High	Lowest	Mid	Low	Low	1:1
Low	Low	High	Lowest	Mid	Low	Mid	1:1
Low	Low	High	Lowest	Mid	Low	High	1:1
Low	Low	High	Lowest	Mid	Mid	Mid	1:1
Low	Low	High	Lowest	Mid	Mid	High	1:1
Low	Low	High	Lowest	Mid	High	Mid	1:1
Low	Low	High	Lowest	Mid	Mid	High	1:4
Low	Low	High	Lowest	Mid	High	Mid	1:4
Low	Low	High	Lowest	High	n/a	n/a	n/a
Low	Low	High	Lowest	High	Low	Mid	n/a
Low	Low	High	Lowest	High	Mid	Mid	n/a
Low	Low	High	Lowest	High	Mid	High	n/a
Low	Low	High	Lowest	High	High	Low	n/a
Low	Low	High	Lowest	High	High	High	n/a
Low	Low	High	Lowest	High	Low	Low	4:1
Low	Low	High	Lowest	High	Low	Mid	4:1
Low	Low	High	Lowest	High	Mid	Mid	4:1
Low	Low	High	Lowest	High	Mid	High	4:1
Low	Low	High	Lowest	High	High	Low	4:1
Low	Low	High	Lowest	High	High	Mid	4:1
Low	Low	High	Lowest	High	High	High	4:1
Low	Low	High	Lowest	High	Low	Mid	1:1
Low	Low	High	Lowest	High	Mid	Mid	1:1
Low	Low	High	Lowest	High	Mid	High	1:1
Low	Low	High	Lowest	High	High	Mid	1:1
Low	Low	High	Lowest	High	High	High	1:1
Mid	Low	Mid	Lowest	n/a	n/a	n/a	n/a
Mid	Low	Mid	Lowest	Low	n/a	n/a	n/a
Mid	Low	Mid	Lowest	Low	Low	Low	n/a
Mid	Low	Mid	Lowest	Low	Mid	Low	n/a

μ	Bottleneck Size	К	Infection Duration	Recombination	Ξ	Burst Size	DFE
Mid	Low	Mid	Lowest	Low	Low	Low	4:1
Mid	Low	Mid	Lowest	Low	Low	Mid	4:1
Mid	Low	Mid	Lowest	Low	Low	High	4:1
Mid	Low	Mid	Lowest	Low	Mid	Low	4:1
Mid	Low	Mid	Lowest	Low	Low	Low	1:1
Mid	Low	Mid	Lowest	Low	Low	Mid	1:1
Mid	Low	Mid	Lowest	Low	Low	High	1:1
Mid	Low	Mid	Lowest	Low	Mid	Low	1:1
Mid	Low	Mid	Lowest	Low	Low	Low	1:4
Mid	Low	Mid	Lowest	Low	Low	Mid	1:4
Mid	Low	Mid	Lowest	Low	Mid	Low	1:4
Mid	Low	Mid	Lowest	Low	High	Low	1:4
Mid	Low	Mid	Lowest	Mid	n/a	n/a	n/a
Mid	Low	Mid	Lowest	Mid	Low	Low	n/a
Mid	Low	Mid	Lowest	Mid	Low	Mid	n/a
Mid	Low	Mid	Lowest	Mid	Mid	Low	n/a
Mid	Low	Mid	Lowest	Mid	Low	Low	4:1
Mid	Low	Mid	Lowest	Mid	Low	Mid	4:1
Mid	Low	Mid	Lowest	Mid	Mid	Low	4:1
Mid	Low	Mid	Lowest	Mid	Low	Low	1:1
Mid	Low	Mid	Lowest	Mid	Low	Mid	1:1
Mid	Low	Mid	Lowest	Mid	Low	High	1:1
Mid	Low	Mid	Lowest	Mid	Mid	Low	1:1
Mid	Low	Mid	Lowest	Mid	Low	Low	1:4
Mid	Low	Mid	Lowest	Mid	Low	Mid	1:4
Mid	Low	Mid	Lowest	Mid	Low	High	1:4
Mid	Low	Mid	Lowest	Mid	Mid	Low	1:4
Mid	Low	Mid	Lowest	Mid	Mid	Mid	1:4
Mid	Low	Mid	Lowest	Mid	High	Low	1:4
Mid	Low	Mid	Lowest	High	n/a	n/a	n/a
Mid	Low	Mid	Lowest	High	Low	Low	n/a
Mid	Low	Mid	Lowest	High	Low	Mid	n/a
Mid	Low	Mid	Lowest	High	Mid	Low	n/a
Mid	Low	Mid	Lowest	High	Low	Low	4:1
Mid	Low	Mid	Lowest	High	Low	Mid	4:1
Mid	Low	Mid	Lowest	High	Low	High	4:1
Mid	Low	Mid	Lowest	High	Mid	Low	4:1
Mid	Low	Mid	Lowest	High	Low	Low	1:1
Mid	Low	Mid	Lowest	High	Low	Mid	1:1
Mid	Low	Mid	Lowest	High	Mid	Low	1:1
Mid	Low	Mid	Lowest	High	Low	Low	1:4

μ	Bottleneck Size	К	Infection Duration	Recombination	Ξ	Burst Size	DFE
Mid	Low	Mid	Lowest	High	Low	Mid	1:4
Mid	Low	Mid	Lowest	High	Low	High	1:4
Mid	Low	Mid	Lowest	High	Mid	Low	1:4
Mid	Low	Mid	Lowest	High	High	Low	1:4
Mid	Low	High	Lowest	n/a	n/a	n/a	n/a
Mid	Low	High	Lowest	Low	n/a	n/a	n/a
Mid	Low	High	Lowest	Low	Low	Low	n/a
Mid	Low	High	Lowest	Low	Low	Mid	n/a
Mid	Low	High	Lowest	Low	Low	High	n/a
Mid	Low	High	Lowest	Low	Mid	Low	n/a
Mid	Low	High	Lowest	Low	Low	Low	4:1
Mid	Low	High	Lowest	Low	Low	Mid	4:1
Mid	Low	High	Lowest	Low	Low	High	4:1
Mid	Low	High	Lowest	Low	Mid	Low	4:1
Mid	Low	High	Lowest	Low	High	Low	4:1
Mid	Low	High	Lowest	Low	Low	Low	1:1
Mid	Low	High	Lowest	Low	Low	Mid	1:1
Mid	Low	High	Lowest	Low	Low	High	1:1
Mid	Low	High	Lowest	Low	Mid	Low	1:1
Mid	Low	High	Lowest	Low	High	Low	1:1
Mid	Low	High	Lowest	Low	Low	Low	1:4
Mid	Low	High	Lowest	Low	Low	Mid	1:4
Mid	Low	High	Lowest	Low	Low	High	1:4
Mid	Low	High	Lowest	Low	Mid	Low	1:4
Mid	Low	High	Lowest	Low	Mid	Mid	1:4
Mid	Low	High	Lowest	Low	High	Low	1:4
Mid	Low	High	Lowest	Mid	n/a	n/a	n/a
Mid	Low	High	Lowest	Mid	Low	Low	n/a
Mid	Low	High	Lowest	Mid	Low	Mid	n/a
Mid	Low	High	Lowest	Mid	Mid	Low	n/a
Mid	Low	High	Lowest	Mid	Low	Low	4:1
Mid	Low	High	Lowest	Mid	Low	Mid	4:1
Mid	Low	High	Lowest	Mid	Low	High	4:1
Mid	Low	High	Lowest	Mid	Mid	Low	4:1
Mid	Low	High	Lowest	Mid	Low	Low	1:1
Mid	Low	High	Lowest	Mid	Low	Mid	1:1
Mid	Low	High	Lowest	Mid	Low	High	1:1
Mid	Low	High	Lowest	Mid	Mid	Low	1:1
Mid	Low	High	Lowest	Mid	Low	Mid	1:4
Mid	Low	High	Lowest	Mid	Low	High	1:4
Mid	Low	High	Lowest	Mid	Mid	Low	1:4

μ	Bottleneck Size	К	Infection Duration	Recombination	Ξ	Burst Size	DFE
Mid	Low	High	Lowest	Mid	Mid	Mid	1:4
Mid	Low	High	Lowest	Mid	High	Mid	1:4
Mid	Low	High	Lowest	High	n/a	n/a	n/a
Mid	Low	High	Lowest	High	Low	Low	n/a
Mid	Low	High	Lowest	High	Low	Mid	n/a
Mid	Low	High	Lowest	High	Low	High	n/a
Mid	Low	High	Lowest	High	Mid	Low	n/a
Mid	Low	High	Lowest	High	Low	Low	4:1
Mid	Low	High	Lowest	High	Low	Mid	4:1
Mid	Low	High	Lowest	High	Low	High	4:1
Mid	Low	High	Lowest	High	Mid	Low	4:1
Mid	Low	High	Lowest	High	Low	Low	1:1
Mid	Low	High	Lowest	High	Low	Mid	1:1
Mid	Low	High	Lowest	High	Low	High	1:1
Mid	Low	High	Lowest	High	Mid	Low	1:1
Mid	Low	High	Lowest	High	High	Low	1:1
Mid	Low	High	Lowest	High	Low	Low	1:4
Mid	Low	High	Lowest	High	Low	Mid	1:4
Mid	Low	High	Lowest	High	Low	High	1:4
Mid	Low	High	Lowest	High	Mid	Mid	1:4
Mid	Low	High	Lowest	High	High	Low	1:4
High	Low	High	Lowest	Low	Low	Low	1:4
High	Low	High	Lowest	Mid	Low	Low	1:4
High	Low	High	Lowest	High	Low	Mid	1:4
Low	Low	Low	Low	Low	Mid	High	1:1
Low	Low	Low	Low	Low	Low	Low	1:4
Low	Low	Low	Low	Low	Low	Mid	1:4
Low	Low	Low	Low	Low	Low	High	1:4
Low	Low	Low	Low	Low	Mid	Low	1:4
Low	Low	Low	Low	Low	Mid	Mid	1:4
Low	Low	Low	Low	Low	Mid	High	1:4
Low	Low	Low	Low	Low	High	Low	1:4
Low	Low	Low	Low	Low	High	Mid	1:4
Low	Low	Low	Low	Low	High	High	1:4
Low	Low	Low	Low	Mid	Mid	High	1:1
Low	Low	Low	Low	Mid	Low	Low	1:4
Low	Low	Low	Low	Mid	Low	Mid	1:4
Low	Low	Low	Low	Mid	Low	High	1:4
Low	Low	Low	Low	Mid	Mid	Low	1:4
Low	Low	Low	Low	Mid	Mid	Mid	1:4
Low	Low	Low	Low	Mid	Mid	High	1:4

μ	Bottleneck Size	К	Infection Duration	Recombination	Ξ	Burst Size	DFE
Low	Low	Low	Low	Mid	High	Low	1:4
Low	Low	Low	Low	Mid	High	Mid	1:4
Low	Low	Low	Low	Mid	High	High	1:4
Low	Low	Low	Low	High	Mid	High	1:1
Low	Low	Low	Low	High	Low	Low	1:4
Low	Low	Low	Low	High	Low	Mid	1:4
Low	Low	Low	Low	High	Low	High	1:4
Low	Low	Low	Low	High	Mid	Low	1:4
Low	Low	Low	Low	High	Mid	High	1:4
Low	Low	Low	Low	High	High	Low	1:4
Low	Low	Low	Low	High	High	High	1:4
Low	Low	Mid	Low	n/a	n/a	n/a	n/a
Low	Low	Mid	Low	Low	n/a	n/a	n/a
Low	Low	Mid	Low	Low	Low	Low	n/a
Low	Low	Mid	Low	Low	Low	Mid	n/a
Low	Low	Mid	Low	Low	Low	High	n/a
Low	Low	Mid	Low	Low	Mid	Low	n/a
Low	Low	Mid	Low	Low	Low	Mid	4:1
Low	Low	Mid	Low	Low	Low	High	4:1
Low	Low	Mid	Low	Low	Mid	Low	4:1
Low	Low	Mid	Low	Low	Low	Mid	1:1
Low	Low	Mid	Low	Low	Low	High	1:1
Low	Low	Mid	Low	Low	Mid	Low	1:1
Low	Low	Mid	Low	Low	High	Low	1:1
Low	Low	Mid	Low	Low	Low	High	1:4
Low	Low	Mid	Low	Low	Mid	Mid	1:4
Low	Low	Mid	Low	Low	Mid	High	1:4
Low	Low	Mid	Low	Low	High	Low	1:4
Low	Low	Mid	Low	Mid	n/a	n/a	n/a
Low	Low	Mid	Low	Mid	Low	Low	n/a
Low	Low	Mid	Low	Mid	Low	Mid	n/a
Low	Low	Mid	Low	Mid	Low	High	n/a
Low	Low	Mid	Low	Mid	Low	Low	4:1
Low	Low	Mid	Low	Mid	Low	Mid	4:1
Low	Low	Mid	Low	Mid	Low	High	4:1
Low	Low	Mid	Low	Mid	Mid	Low	4:1
Low	Low	Mid	Low	Mid	High	Low	1:1
Low	Low	Mid	Low	Mid	Low	High	1:4
Low	Low	Mid	Low	Mid	Mid	Mid	1:4
Low	Low	Mid	Low	Mid	Mid	High	1:4
Low	Low	Mid	Low	Mid	High	Low	1:4

μ	Bottleneck Size	К	Infection Duration	Recombination	Ξ	Burst Size	DFE
Low	Low	Mid	Low	Mid	High	Mid	1:4
Low	Low	Mid	Low	Mid	High	High	1:4
Low	Low	Mid	Low	High	n/a	n/a	n/a
Low	Low	Mid	Low	High	Low	Low	n/a
Low	Low	Mid	Low	High	Low	Mid	n/a
Low	Low	Mid	Low	High	Low	High	n/a
Low	Low	Mid	Low	High	Low	Mid	4:1
Low	Low	Mid	Low	High	Low	High	4:1
Low	Low	Mid	Low	High	Mid	Low	4:1
Low	Low	Mid	Low	High	Low	Low	1:1
Low	Low	Mid	Low	High	Mid	Low	1:1
Low	Low	Mid	Low	High	Mid	Mid	1:1
Low	Low	Mid	Low	High	Mid	Mid	1:4
Low	Low	Mid	Low	High	Mid	High	1:4
Low	Low	Mid	Low	High	High	Low	1:4
Low	Low	Mid	Low	High	High	Mid	1:4
Low	Low	Mid	Low	High	High	High	1:4
Low	Low	High	Low	Low	n/a	n/a	n/a
Low	Low	High	Low	Low	Low	Low	n/a
Low	Low	High	Low	Low	Low	Mid	n/a
Low	Low	High	Low	Low	Mid	Low	n/a
Low	Low	High	Low	Low	High	Low	n/a
Low	Low	High	Low	Low	Low	Low	4:1
Low	Low	High	Low	Low	Mid	Mid	4:1
Low	Low	High	Low	Low	High	Low	4:1
Low	Low	High	Low	Low	Low	High	1:1
Low	Low	High	Low	Low	Mid	Low	1:1
Low	Low	High	Low	Low	Mid	Mid	1:1
Low	Low	High	Low	Low	High	Low	1:1
Low	Low	High	Low	Low	Mid	Mid	1:4
Low	Low	High	Low	Low	Mid	High	1:4
Low	Low	High	Low	Low	High	Low	1:4
Low	Low	High	Low	Low	High	Mid	1:4
Low	Low	High	Low	Low	High	High	1:4
Low	Low	High	Low	Mid	n/a	n/a	n/a
Low	Low	High	Low	Mid	Low	Low	n/a
Low	Low	High	Low	Mid	Low	High	n/a
Low	Low	High	Low	Mid	Mid	Low	n/a
Low	Low	High	Low	Mid	High	Low	n/a
Low	Low	High	Low	Mid	Low	Low	4:1
Low	Low	High	Low	Mid	Low	Mid	4:1

μ	Bottleneck Size	К	Infection Duration	Recombination	Ξ	Burst Size	DFE
Low	Low	High	Low	Mid	Low	High	4:1
Low	Low	High	Low	Mid	Mid	Low	4:1
Low	Low	High	Low	Mid	Mid	Mid	4:1
Low	Low	High	Low	Mid	High	Low	4:1
Low	Low	High	Low	Mid	Low	Mid	1:1
Low	Low	High	Low	Mid	Mid	Low	1:1
Low	Low	High	Low	Mid	Mid	Mid	1:1
Low	Low	High	Low	Mid	High	Low	1:1
Low	Low	High	Low	Mid	High	Mid	1:1
Low	Low	High	Low	Mid	Low	Low	1:4
Low	Low	High	Low	Mid	Mid	Mid	1:4
Low	Low	High	Low	Mid	Mid	High	1:4
Low	Low	High	Low	Mid	High	Mid	1:4
Low	Low	High	Low	Mid	High	High	1:4
Low	Low	High	Low	High	n/a	n/a	n/a
Low	Low	High	Low	High	Low	Low	n/a
Low	Low	High	Low	High	Low	Mid	n/a
Low	Low	High	Low	High	Mid	Low	n/a
Low	Low	High	Low	High	High	Low	n/a
Low	Low	High	Low	High	Low	Mid	4:1
Low	Low	High	Low	High	Mid	Mid	4:1
Low	Low	High	Low	High	High	Low	4:1
Low	Low	High	Low	High	Low	Low	1:1
Low	Low	High	Low	High	Low	Mid	1:1
Low	Low	High	Low	High	Mid	Mid	1:1
Low	Low	High	Low	High	High	High	1:1
Low	Low	High	Low	High	Low	High	1:4
Low	Low	High	Low	High	Mid	Mid	1:4
Low	Low	High	Low	High	Mid	High	1:4
Low	Low	High	Low	High	High	Mid	1:4
Low	Low	High	Low	High	High	High	1:4
Mid	Low	Mid	Low	Low	Low	Low	1:4
Mid	Low	Mid	Low	Low	Low	Mid	1:4
Mid	Low	Mid	Low	Low	Mid	Low	1:4
Mid	Low	Mid	Low	Mid	Low	Low	1:4
Mid	Low	Mid	Low	Mid	Low	Mid	1:4
Mid	Low	Mid	Low	Mid	Mid	Low	1:4
Mid	Low	Mid	Low	High	Low	Low	1:4
Mid	Low	Mid	Low	High	Low	Mid	1:4
Mid	Low	Mid	Low	High	Mid	Low	1:4
Mid	Low	High	Low	Low	n/a	n/a	n/a

μ	Bottleneck Size	К	Infection Duration	Recombination	Ξ	Burst Size	DFE
Mid	Low	High	Low	Low	Low	Low	n/a
Mid	Low	High	Low	Low	Low	Mid	n/a
Mid	Low	High	Low	Low	Low	Low	4:1
Mid	Low	High	Low	Low	Low	Low	1:1
Mid	Low	High	Low	Low	Low	Low	1:4
Mid	Low	High	Low	Mid	n/a	n/a	n/a
Mid	Low	High	Low	Mid	Low	Low	n/a
Mid	Low	High	Low	Mid	Low	Low	4:1
Mid	Low	High	Low	Mid	Low	Mid	4:1
Mid	Low	High	Low	Mid	Low	Low	1:1
Mid	Low	High	Low	Mid	Low	Mid	1:1
Mid	Low	High	Low	Mid	Mid	Low	1:1
Mid	Low	High	Low	Mid	Low	Low	1:4
Mid	Low	High	Low	Mid	Low	Mid	1:4
Mid	Low	High	Low	Mid	Low	High	1:4
Mid	Low	High	Low	Mid	Mid	Low	1:4
Mid	Low	High	Low	High	n/a	n/a	n/a
Mid	Low	High	Low	High	Low	Low	4:1
Mid	Low	High	Low	High	Low	Low	1:1
Mid	Low	High	Low	High	Low	Mid	1:1
Mid	Low	High	Low	High	Mid	Low	1:1
Mid	Low	High	Low	High	Low	Low	1:4
Mid	Low	High	Low	High	Low	Mid	1:4
Mid	Low	High	Low	High	Low	High	1:4
Mid	Low	High	Low	High	Mid	Low	1:4
Mid	Low	High	Low	High	High	Low	1:4
Low	Low	Low	Mid	Low	Mid	High	1:1
Low	Low	Low	Mid	Low	Mid	Mid	1:4
Low	Low	Low	Mid	Low	Mid	High	1:4
Low	Low	Low	Mid	Mid	Mid	High	1:1
Low	Low	Low	Mid	Mid	Mid	High	1:4
Low	Low	Low	Mid	High	Mid	High	1:1
Low	Low	Low	Mid	High	Low	High	1:4
Low	Low	Low	Mid	High	Mid	High	1:4
Low	Low	Low	Mid	High	High	Mid	1:4
Low	Low	Mid	Mid	n/a	n/a	n/a	n/a
Low	Low	Mid	Mid	Low	n/a	n/a	n/a
Low	Low	Mid	Mid	Low	Low	Low	n/a
Low	Low	Mid	Mid	Low	Low	Low	4:1
Low	Low	Mid	Mid	Low	Mid	Low	4:1
Low	Low	Mid	Mid	Low	Low	Low	1:1

μ	Bottleneck Size	К	Infection Duration	Recombination	Ξ	Burst Size	DFE
Low	Low	Mid	Mid	Low	Low	Mid	1:1
Low	Low	Mid	Mid	Low	Low	High	1:1
Low	Low	Mid	Mid	Low	Mid	Low	1:1
Low	Low	Mid	Mid	Low	Low	Low	1:4
Low	Low	Mid	Mid	Low	Low	Mid	1:4
Low	Low	Mid	Mid	Low	Low	High	1:4
Low	Low	Mid	Mid	Low	Mid	Low	1:4
Low	Low	Mid	Mid	Mid	Low	Low	4:1
Low	Low	Mid	Mid	Mid	Mid	Low	4:1
Low	Low	Mid	Mid	Mid	Low	Low	1:1
Low	Low	Mid	Mid	Mid	Low	Mid	1:1
Low	Low	Mid	Mid	Mid	Mid	Low	1:1
Low	Low	Mid	Mid	Mid	Low	Mid	1:4
Low	Low	Mid	Mid	Mid	Low	High	1:4
Low	Low	Mid	Mid	Mid	Mid	Low	1:4
Low	Low	Mid	Mid	High	n/a	n/a	n/a
Low	Low	Mid	Mid	High	Low	Mid	1:1
Low	Low	Mid	Mid	High	Low	Low	1:4
Low	Low	Mid	Mid	High	Low	Mid	1:4
Low	Low	Mid	Mid	High	Low	High	1:4
Low	Low	Mid	Mid	High	Mid	Low	1:4
Low	Low	High	Mid	n/a	n/a	n/a	n/a
Low	Low	High	Mid	Low	n/a	n/a	n/a
Low	Low	High	Mid	Low	Low	Mid	n/a
Low	Low	High	Mid	Low	Mid	Low	n/a
Low	Low	High	Mid	Low	Low	Mid	4:1
Low	Low	High	Mid	Low	Low	High	4:1
Low	Low	High	Mid	Low	Low	Low	1:1
Low	Low	High	Mid	Low	Low	Mid	1:1
Low	Low	High	Mid	Low	Low	High	1:1
Low	Low	High	Mid	Low	Mid	Low	1:1
Low	Low	High	Mid	Low	Low	Mid	1:4
Low	Low	High	Mid	Low	Mid	Mid	1:4
Low	Low	High	Mid	Low	High	Low	1:4
Low	Low	High	Mid	Mid	n/a	n/a	n/a
Low	Low	High	Mid	Mid	Low	Low	n/a
Low	Low	High	Mid	Mid	Low	Mid	n/a
Low	Low	High	Mid	Mid	Mid	Low	n/a
Low	Low	High	Mid	Mid	Low	Low	4:1
Low	Low	High	Mid	Mid	Low	Low	1:1
Low	Low	High	Mid	Mid	Low	Mid	1:1

μ	Bottleneck Size	К	Infection Duration	Recombination	Ξ	Burst Size	DFE
Low	Low	High	Mid	Mid	Low	High	1:4
Low	Low	High	Mid	Mid	Mid	Mid	1:4
Low	Low	High	Mid	Mid	High	Low	1:4
Low	Low	High	Mid	High	n/a	n/a	n/a
Low	Low	High	Mid	High	Low	Low	n/a
Low	Low	High	Mid	High	Low	Mid	n/a
Low	Low	High	Mid	High	Low	High	n/a
Low	Low	High	Mid	High	Mid	Low	n/a
Low	Low	High	Mid	High	Low	Mid	4:1
Low	Low	High	Mid	High	Low	High	4:1
Low	Low	High	Mid	High	Mid	Low	4:1
Low	Low	High	Mid	High	Low	Low	1:1
Low	Low	High	Mid	High	Low	High	1:1
Low	Low	High	Mid	High	High	Low	1:1
Low	Low	High	Mid	High	Low	High	1:4
Low	Low	High	Mid	High	Mid	Low	1:4
Low	Low	High	Mid	High	Mid	Mid	1:4
Low	Low	High	Mid	High	High	Low	1:4
Mid	Low	High	Mid	Low	Low	Mid	1:4
Mid	Low	High	Mid	Mid	Low	Mid	1:4
Mid	Low	High	Mid	High	Low	Mid	1:4
Low	Low	Low	High	Low	Mid	Mid	1:4
Low	Low	Low	High	Low	Mid	High	1:4
Low	Low	Low	High	Mid	Mid	Mid	1:4
Low	Low	Low	High	Mid	Mid	High	1:4
Low	Low	Low	High	High	Mid	High	1:4
Low	Low	Mid	High	Low	Low	Low	1:4
Low	Low	Mid	High	Low	Low	Mid	1:4
Low	Low	Mid	High	Low	Mid	Low	1:4
Low	Low	Mid	High	Mid	Low	Low	1:4
Low	Low	Mid	High	Mid	Low	Mid	1:4
Low	Low	Mid	High	Mid	Low	High	1:4
Low	Low	Mid	High	Mid	Mid	Low	1:4
Low	Low	Mid	High	High	Low	Low	1:4
Low	Low	Mid	High	High	Low	Mid	1:4
Low	Low	Mid	High	High	Mid	Low	1:4
Low	Low	High	High	n/a	n/a	n/a	n/a
Low	Low	High	High	Low	Low	Low	4:1
Low	Low	High	High	Low	Low	Mid	4:1
Low	Low	High	High	Low	Low	Low	1:1
Low	Low	High	High	Low	Low	Mid	1:1

μ	Bottleneck Size	К	Infection Duration	Recombination	Ξ	Burst Size	DFE
Low	Low	High	High	Low	Mid	Low	1:1
Low	Low	High	High	Low	Low	Mid	1:4
Low	Low	High	High	Low	Low	High	1:4
Low	Low	High	High	Low	Mid	Low	1:4
Low	Low	High	High	Mid	Low	Low	4:1
Low	Low	High	High	Mid	Low	Low	1:1
Low	Low	High	High	Mid	Low	Mid	1:1
Low	Low	High	High	Mid	Mid	Low	1:1
Low	Low	High	High	Mid	Low	Low	1:4
Low	Low	High	High	Mid	Low	Mid	1:4
Low	Low	High	High	Mid	Low	High	1:4
Low	Low	High	High	Mid	Mid	Low	1:4
Low	Low	High	High	High	n/a	n/a	n/a
Low	Low	High	High	High	Low	Low	4:1
Low	Low	High	High	High	Low	Mid	1:1
Low	Low	High	High	High	Mid	Low	1:1
Low	Low	High	High	High	Low	Low	1:4
Low	Low	High	High	High	Low	Mid	1:4
Low	Low	High	High	High	Low	High	1:4
Low	Low	High	High	High	Mid	Low	1:4

515 Supplemental Table 2. List of models with replicates that failed to complete due to exceeding allocated

516 memory.

517 Mutation Rate (μ)	Carrying Capacity (<i>K</i>)	Bottleneck Size	Infection Duration	Recombination Rate (<i>R</i>)	Progeny Skew Probability (<i>Ξ</i>)	Burst Size	DFE	Missing Reps
High	High	Mid	High	Mid	High	High	n/a	1
High	High	Mid	Mid	High	High	High	n/a	4
High	High	High	Mid	High	High	High	n/a	5
High	High	Mid	High	High	High	High	n/a	2
High	High	High	High	High	High	High	n/a	5
High	High	High	Mid	High	High	High	4,1	1
High	High	Mid	High	High	High	High	4,1	5
High	High	High	High	High	High	High	4,1	3

- 518 Supplemental Table 3. Order of models presented in Figure 3, Supplemental Figure 1, and Supplemental
- Figure 2 as lines (range) and points (mean value). Note that for each figure the mutation rate (μ), initial
- 520 bottleneck size, and carrying capacity (*K*) are the same for all models. The infection duration varies
- 521 between models as described in figure captions. Models with no completed replicates (Supplemental
- 522 Table 2) appear as gaps between neighboring models.

Order	R	Ξ	Burst	DFE
1	n/a	n/a	 n/a	n/a
2	low	n/a	n/a	n/a
3	Mid	n/a	n/a	n/a
4	High	n/a	n/a	n/a
5	low	low	low	n/a
6	Mid	Low	Low	n/a
7	High	Low	Low	n/a
8	Low	Mid	Low	n/a
9	Mid	Mid	Low	n/a
10	High	Mid	Low	n/a
11	Low	High	Low	n/a
12	Mid	High	Low	n/a
13	High	High	Low	n/a
14	Low	Low	Mid	n/a
15	Mid	Low	Mid	n/a
16	High	Low	Mid	n/a
17	Low	Mid	Mid	, n/a
18	Mid	Mid	Mid	n/a
19	High	Mid	Mid	n/a
20	Low	High	Mid	n/a
21	Mid	High	Mid	n/a
22	High	High	Mid	n/a
23	Low	Low	High	n/a
24	Mid	Low	High	n/a
25	High	Low	High	n/a
26	Low	Mid	High	n/a
27	Mid	Mid	High	n/a
28	High	Mid	High	n/a
29	Low	High	High	n/a
30	Mid	High	High	n/a
31	High	High	High	n/a
32	Low	Low	Low	4:1

Order	R	Ξ	Burst Size	DFE
33	Mid	Low	Low	4:1
34	High	Low	Low	4:1
35	Low	Mid	Low	4:1
36	Mid	Mid	Low	4:1
37	High	Mid	Low	4:1
38	Low	High	Low	4:1
39	Mid	High	Low	4:1
40	High	High	Low	4:1
41	Low	Low	Mid	4:1
42	Mid	Low	Mid	4:1
43	High	Low	Mid	4:1
44	Low	Mid	Mid	4:1
45	Mid	Mid	Mid	4:1
46	High	Mid	Mid	4:1
47	Low	High	Mid	4:1
48	Mid	High	Mid	4:1
49	High	High	Mid	4:1
50	Low	Low	High	4:1
51	Mid	Low	High	4:1
52	High	Low	High	4:1
53	Low	Mid	High	4:1
54	Mid	Mid	High	4:1
55	High	Mid	High	4:1
56	Low	High	High	4:1
57	Mid	High	High	4:1
58	High	High	High	4:1
59	Low	Low	Low	1:1
60	Mid	Low	Low	1:1
61	High	Low	Low	1:1
62	Low	Mid	Low	1:1
63	Mid	Mid	Low	1:1
64	High	Mid	Low	1:1
65	Low	High	Low	1:1
66	Mid	High	Low	1:1
67	High	High	Low	1:1
68	Low	Low	Mid	1:1
69	Mid	Low	Mid	1:1
70	High	Low	Mid	1:1
71	Low	Mid	Mid	1:1
72	Mid	Mid	Mid	1:1
73	High	Mid	Mid	1:1

Order	R	Ξ	Burst Size	DFE
74	Low	High	Mid	1:1
75	Mid	High	Mid	1:1
76	High	High	Mid	1:1
77	Low	Low	High	1:1
78	Mid	Low	High	1:1
79	High	Low	High	1:1
80	Low	Mid	High	1:1
81	Mid	Mid	High	1:1
82	High	Mid	High	1:1
83	Low	High	High	1:1
84	Mid	High	High	1:1
85	High	High	High	1:1
86	Low	Low	Low	1:4
87	Mid	Low	Low	1:4
88	High	Low	Low	1:4
89	Low	Mid	Low	1:4
90	Mid	Mid	Low	1:4
91	High	Mid	Low	1:4
92	Low	High	Low	1:4
93	Mid	High	Low	1:4
94	High	High	Low	1:4
95	Low	Low	Mid	1:4
96	Mid	Low	Mid	1:4
97	High	Low	Mid	1:4
98	Low	Mid	Mid	1:4
99	Mid	Mid	Mid	1:4
100	High	Mid	Mid	1:4
101	Low	High	Mid	1:4
102	Mid	High	Mid	1:4
103	High	High	Mid	1:4
104	Low	Low	High	1:4
105	Mid	Low	High	1:4
106	High	Low	High	1:4
107	Low	Mid	High	1:4
108	Mid	Mid	High	1:4
109	High	Mid	High	1:4
110	Low	High	High	1:4
111	Mid	High	High	1:4
112	High	High	High	1:4

bioRxiv preprint doi: https://doi.org/10.1101/2023.07.13.548462; this version posted July 17, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.



Supplemental Figure 1. Each line represents the range of filtered SNPs for a particular model using a 525 sampling of 1000 genomes; each point is the mean of that model's replicates. All models in this figure 526 527 used the lowest bottleneck size (*i.e.*, 5); panels increase from left to right in the value of carrying capacity 528 used and increase from top to bottom in the value of mutation rate used. Within each panel, dashed lines separate models into subpanels with different infection durations, increasing from left to right. Within 529 530 each subpanel the order of the models is the same and is detailed in Supplemental Table 3. The blue, 531 horizontal line represents the threshold of 5 SNPs used in this study to accept or reject a potential model 532 (note that Y-axes differ by row).

bioRxiv preprint doi: https://doi.org/10.1101/2023.07.13.548462; this version posted July 17, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.



533

Supplemental Figure 2. Each line represents the range of filtered SNPs for a particular model using a 534 sampling of 1000 genomes; each point is the mean of that model's replicates. All models in this figure 535 536 used the high bottleneck size (i.e., 100); panels increase from left to right in the value of carrying capacity used and increase from top to bottom in the value of mutation rate used. Within each panel, dashed lines 537 separate models into subpanels with different infection durations, increasing from left to right. Within 538 539 each subpanel the order of the models is the same and is detailed in Supplemental Table 3. The blue, 540 horizontal line represents the threshold of 5 SNPs used in this study to accept or reject a potential model 541 (note that Y-axes differ by row).